Pyroglutamate formation at peptide N-termini
A peptide that starts with glutamine or glutamic acid can close its own N-terminus into a lactam ring, pyroglutamate, losing 17 or 18 Da and its free amine in a reaction that needs no enzyme.
When the first residue of a chain is glutamine, its free alpha-amine can attack the side-chain amide and release ammonia, leaving a five-membered pyroglutamyl ring (pGlu, written pE). An N-terminal glutamic acid can do the same by losing water. The product carries no free N-terminal amine, so it blocks Edman sequencing, changes charge, and shows up as a −17 Da (from Gln) or −18 Da (from Glu) species in the mass spectrum, usually resolved from the parent on reversed-phase or ion-exchange methods.
Glutamine cyclizes far faster than glutamic acid, and conditions matter more than pH. Dick and colleagues, Biotechnology and Bioengineering, 2007 (PMID 17099914) used two model peptides and an antibody with an N-terminal glutamine and found the cyclization spontaneous and strongly dependent on temperature and buffer composition, with less dependence on pH. Seifert and colleagues, Bioorganic Chemistry, 2015 (PMID 25981125) showed with kinetic isotope effects that phosphate ions accelerate the non-enzymatic reaction by promoting synchronized proton transfers, the same mode of catalysis used by the enzyme glutaminyl cyclase. Phosphate buffers are a known accelerant for this reason.
Glutamic acid is slower but not inert. Chelius and colleagues, Analytical Chemistry, 2006 (PMID 16579622) reported the first in vitro evidence that N-terminal glutamic acid converts to pyroglutamate in recombinant antibodies, detectable after a few weeks at 37 and 45 °C. Formation was lowest near pH 6.2 and rose at pH 4 and pH 8, with a half-life of about nine months in pH 4.1 buffer at 45 °C. The practical reading for a lab: check whether a sequence begins with Q or E, keep material lyophilized until use, avoid long holds in phosphate solution, and look for the −17 or −18 Da species on the certificate of analysis. Some sequences are synthesized with pGlu already in place, in which case the ring is the intended structure, not a degradant. This note summarizes published peptide chemistry. It is not dosing or human-use guidance.